IPP Bureau
Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
By IPP Bureau - January 18, 2023
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
Glenmark to divest select dermatology brands for Rs. 340.48 Cr
By IPP Bureau - January 18, 2023
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba
By IPP Bureau - January 18, 2023
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Cipla launches Cippoint
By IPP Bureau - January 18, 2023
Point-of-Care solution to facilitate clinicians in quick and effective decision making
AI to drive digital mammography equipment market in South Korea during 2015-2030: GlobalData
By IPP Bureau - January 18, 2023
AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering
By IPP Bureau - January 18, 2023
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
By IPP Bureau - January 17, 2023
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram
By IPP Bureau - January 17, 2023
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
By IPP Bureau - January 17, 2023
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Vikas Lifecare’s in-house R&D Unit gets DSIR recognition
By IPP Bureau - January 17, 2023
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
Lonza completes expansion to Solid Form Services Facility at Bend (US) site
By IPP Bureau - January 17, 2023
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
USFDA conducts PAI and GMP inspection of Piramal Pharma's Sellersville facility
By IPP Bureau - January 16, 2023
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
Global Hospital's hand transplant recipients to participate in Tata Mumbai Marathon 2023
By IPP Bureau - January 16, 2023
Monika and Prathmesh’s determination to participate in the Dream Run to increase awareness serves as a testament to life changing effects of organ transplants and importance of organ donation
Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules
By IPP Bureau - January 16, 2023
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Granules India’s Gagillapur facility completes USFDA inspection
By IPP Bureau - January 16, 2023
The company will respond to these observations within the stipulated time period.
